PROMIS NEUROSCIENCES INC. Deferred Costs, Current
PROMIS NEUROSCIENCES INC. (PMN) had Deferred Costs, Current of $99.56 thousand as of 2024-06-30, per its 10-Q filed 2024-08-08.
Financial Statements › Balance Sheet › Assets › Assets, Current › Deferred Costs, Current
us-gaap:DeferredCostsCurrent · last filed 2024-11-14
- 2024-06-30: Deferred Costs, Current $99.56K.
- 2023-12-31: Deferred Costs, Current $195.63K.
- 2023-06-30: Deferred Costs, Current $12.71K.
- 2023-03-31: Deferred Costs, Current $464.47K.
| Period end | Deferred Costs, Current |
|---|---|
| 2024-06-30 | $99.56K 10-Q · filed 2024-08-08 |
| 2023-12-31 | $195.63K 10-Q · filed 2024-11-14 |
| 2023-06-30 | $12.71K 10-Q · filed 2023-08-14 |
| 2023-03-31 | $464.47K 10-Q · filed 2023-05-15 |
| 2022-09-30 | $470.05K 10-Q · filed 2022-11-14 |
| 2022-06-30 | $176.90K 10-Q · filed 2022-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |